Clinical trials: DR
Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00389818
- Testing
- filgrastim, pegfilgrastim, rituximab
- Where
- 14 sites in United States
- Volunteers
- 43 people
- Sponsor
- AIDS Malignancy Consortium
Acute Myeloid Leukemia (AML)
Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML
This trial will evaluate whether luveltamab tazevibulin is well tolerated and active against a rare form of AML carrying a particular genetic abnormality called CBFA2T3::GLIS2 that arises in infants and children.
- Trial name
- NCT06679582
- Testing
- Luveltamab tazevibulin
- Where
- 36 sites in United States, Austria and 7 more
- Volunteers
- 1 people
- Sponsor
- Sutro Biopharma, Inc.
Type 2 Diabetes Mellitus
Assessing the Effect of Met DR on Plasma Glucose and PK in Subjects With T2DM
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose…
- Trial name
- NCT01804842
- Testing
- Met DR
- Volunteers
- 26 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Gastrointestinal Diseases
Bioequivalence Study of Raperazole 20mg DR Tabs and PARIET® 20 mg DR Tabs Under Fed Conditions
This is an open-label, randomized, single dose, two-sequence, two-periods crossover study, separated by 7 days washout interval from the first Study Drug Administration.
- Trial name
- NCT02605395
- Testing
- IDIAZOLE 20mg DR tabs, PARIET 20 mg DR tabs
- Where
- Egypt
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240108
- Testing
- Rifaximin EIR
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Bausch Health Americas, Inc.
Healthy Subjects
Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects
This study compared the pharmacokinetics (PK) and assessed the safety of delayed-release metformin (Met DR, EFB0027) at two dosage levels, immediate-release metformin (Met IR, ETB0015), and extended-release metformin (Met XR…
- Trial name
- NCT02291510
- Testing
- Met DR, Met XR, Met IR
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Elcelyx Therapeutics, Inc.
Healthy
Lansoprazole 30 mg DR Capsule Fasting Study
The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT01045967
- Testing
- Lansoprazole, Prevacid®
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Diabetic Retinopathy
Integrating DR Into Mainstream Health System in Bangladesh
Diabetes mellitus is a leading cause of death and disability. Diabetic Retinopathy (DR) is an eye disease that affects the eyesight of about 21.3% persons with diabetes in Bangladesh in a way that is irreversible because of the…
- Trial name
- NCT03658980
- Testing
- Health Education Intervention
- Where
- Bangladesh
- Volunteers
- 299 people
- Sponsor
- Hiroshima University
Pacemaker Indication
Master Study for the Investigation of Safety and Efficacy of the EVIA Pacemaker
The objective of this study is to prove the safety and efficacy of the EVIA pacemaker. Primarily, the newly implemented Atrial Capture Control algorithm is evaluated, which automatically measures the right atrial threshold and…
- Trial name
- NCT00916344
- Testing
- EVIA Pacemaker
- Where
- France
- Volunteers
- 175 people
- Sponsor
- Biotronik SE & Co. KG
Healthy
Pantoprazole Sodium 40 mg DR Tablets Under Fasting Conditions
The objective of this study is to compare the relative bioavailability of pantoprazole sodium 40 mg delayed-release tablets ( manufactured by TEVA Pharmaceuticals Industries, Ltd.
- Trial name
- NCT00835588
- Testing
- Pantoprazole Sodium 40 mg delayed-release tablets, PROTONIX® 40 mg delayed-release tablets.
- Where
- 2 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Diabetic Retinopathy
A Single-center, Retrospective Study to Evaluate the Clinical Performance of Artificial Intelligence Medical Assisted Diagnostic Software (VeriSee DR) for Screening of Diabetic Retinopathy in Patients With Diabetes Mellitus
This study is to evaluate the clinical performance of VeriSee DR for DR screening from color fundus photography images in patients with diabetes mellitus.
- Trial name
- NCT04160988
- Where
- Taiwan
- Volunteers
- 703 people
- Sponsor
- Acer Being Health Inc.
Cardiac Pacemaker, Artificial, Cardiac Rhythm Disorder
Aveir DR i2i Study
Prospective, non-randomized, multi-center, international study designed to evaluate the safety and effectiveness of the Aveir™ Dual-Chamber (DR) Leadless Pacemaker system.
- Conditions
- Cardiac Pacemaker, Artificial, Cardiac Rhythm Disorder, Bradycardia
- Trial name
- NCT05252702
- Testing
- Aveir DR Leadless Pacemaker System
- Where
- 78 sites in United States, Austria and 11 more
- Volunteers
- 464 people
- Sponsor
- Abbott Medical Devices
Renal Insufficiency
Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction, or severe kidney dysfunction.
- Trial name
- NCT01658514
- Testing
- Met DR, Met XR
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Elcelyx Therapeutics, Inc.
Healthy
Lansoprazole 30 mg DR Capsule Replicate Food Study
The object of this study is to compare the relative bioavailability of lansoprazole 30 mg delayed-release capsules (manufactured by TEVA Pharmaceutical Industries, Ltd.
- Trial name
- NCT01046084
- Testing
- Lansoprazole, Prevacid®
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA